Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib (Q39568883)

13 September 2017

Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib (English)

1 reference

13 September 2017

1 reference

Giovanni Luca Gravina

1

1 reference

13 September 2017

2

1 reference

13 September 2017

7

1 reference

13 September 2017

5

Corrado Ficorella

1 reference

13 September 2017

Margherita Piccolella

3

1 reference

13 September 2017

Leda Biordi

4

1 reference

13 September 2017

Marcella Motta

6

1 reference

13 September 2017

Vincenzo Tombolini

8

1 reference

13 September 2017

Claudio Festuccia

9

1 reference

13 September 2017

28 March 2011

1 reference

13 September 2017

1 reference

13 September 2017

71

1 reference

13 September 2017

14

1 reference

13 September 2017

1481-1491

1 reference

Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.

13 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21363

Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21363

Growth Factor Receptor Tyrosine Kinase Inhibitors; Clinical Development and Potential for Prostate Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21363

The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21363

Her-2-neu expression and progression toward androgen independence in human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21363

Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21363

Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21363

A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21363

A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21363

Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21363

EPN: a novel epithelial cell line derived from human prostate tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21363

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21363

Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21363

Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21363

Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21363

PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21363

The current state of preclinical prostate cancer animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21363

Acetylation of nuclear receptors in cellular growth and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21363

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21363

Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21363

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21363

Her2 crosstalks with TrkA in a subset of prostate cancer cells: rationale for a guided dual treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21363

21 January 2018

Identifiers

DOI

10.1002/PROS.21363

1 reference

release_6dubemzw3rcnngi6qy46oxan5q

13 September 2017

0 references

1 reference